Patents by Inventor Peter K. Gregersen
Peter K. Gregersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230295729Abstract: Methods of treating and noninvasively detecting progesterone/progestin-resistant infertility are provided. Methods of identifying subjects with infertility as suitable for plant flavonoid treatments are provided.Type: ApplicationFiled: March 13, 2023Publication date: September 21, 2023Inventors: Christine Metz, Peter K. Gregersen
-
Publication number: 20210096137Abstract: Provided is a method of non-invasively diagnosing endometriosis in a subject comprising maintaining or culturing stromal cells, obtained from a menstrual effluent or discharge sample from the subject. Also provided is a method of non-invasively diagnosing fertility in a subject. Also provided is a kit for non-invasively diagnosing endometriosis in a subject. Also provided is a method of treating endometriosis in a subject. Also provided is a method of preventing the progression or development of endometriosis in a subject.Type: ApplicationFiled: March 6, 2019Publication date: April 1, 2021Inventors: Christine Metz, Peter K. Gregersen, Laura Warren
-
Publication number: 20160201130Abstract: Describe herein is a novel CATT-tetranucleotide repeat polymorphism at position ?817 of the human Mif gene that functionally affects the activity of the Macrophage Inhibitory Factor (MIF) promoter in gene reporter assays. Four genotypes are described which comprise 5, 6, 7, or 8-CATT repeat units. Of these, the 5-CATT allele has the lowest level of basal and stimulated MIF promoter activity in vitro. The presence of the low expressing, 5-CATT repeat allele correlated with low disease severity in a cohort of rheumatoid arthritis patients. Methods, compositions and apparatus for detecting this CATT-tetranucleotide repeat polymorphism at position ?817 of the human Mif gene, and for using same for assessing predisposition to severe inflammatory disease, are also disclosed.Type: ApplicationFiled: August 17, 2015Publication date: July 14, 2016Inventors: John A. Baugh, Richard J. Bucala, Smita Chitnis, Seamus C. Donnelly, Peter K. Gregersen, Joanita Monteiro
-
Patent number: 9139877Abstract: Describe herein is a novel CATT-tetranucleotide repeat polymorphism at position ?817 of the human Mif that functionally affects the activity of the Macrophage Inhibitory Factor (MIF) promoter in gene reporter assays. Four genotypes are described which comprise 5, 6, 7, or 8-CATT repeat units. Of these, the 5-CATT allele has the lowest level of basal and stimulated MIF promoter activity in vitro. The presence of the low expressing, 5-CATT repeat allele correlated with low disease severity in a cohort of rheumatoid arthritis patients. Methods, compositions and apparatus for detecting this CATT-tetranucleotide repeat polymorphism at position ?817 of the human Mif gene, and for using same for assessing predisposition to severe inflammatory disease, are also disclosed.Type: GrantFiled: December 6, 2012Date of Patent: September 22, 2015Assignees: Baxalta Incorporated, Baxalta GmbHInventors: John A. Baugh, Richard J. Bucala, Smita Chitnis, Seamus C. Donnelly, Peter K. Gregersen, Joanita Monteiro
-
Patent number: 7910299Abstract: The invention relates to methods and materials involved in diagnosing SLE. More particularly, the invention relates to methods and materials involved in diagnosing SLE, diagnosing severe SLE, and assessing a mammal's susceptibility to develop severe SLE. For example, the invention provides nucleic acid arrays that can be used to diagnose SLE in a mammal. Such arrays can allow clinicians to diagnose SLE based on a simultaneous determination of the expression levels of many genes that are differentially expressed in SLE patients as compared to healthy controls.Type: GrantFiled: October 3, 2006Date of Patent: March 22, 2011Assignees: Regents of the University of Minnesota, The Feinstein Institute for Medical ResearchInventors: Timothy W. Behrens, Emily C. Baechler, Peter K. Gregersen
-
Publication number: 20110027822Abstract: This document relates to methods and materials involved in diagnosing SLE. For example, this document relates to methods and materials involved in diagnosing SLE, diagnosing severe SLE, and assessing a mammal's susceptibility to develop severe SLE. For example, this document provides nucleic acid arrays that can be used to diagnose SLE in a mammal. Such arrays can allow clinicians to diagnose SLE based on a simultaneous determination of the expression levels of many genes that are differentially expressed in SLE patients as compared to healthy controls. In addition, methods and materials for assessing SLE activity, determining the likelihood of experiencing active SLE, and detecting SLE treatment effectiveness are provided herein.Type: ApplicationFiled: August 3, 2009Publication date: February 3, 2011Inventors: Timothy W. Behrens, Emily C. Gillespie, Peter K. Gregersen
-
Publication number: 20100303813Abstract: The present disclosure provides biomarkers that are predictive a subject's responsiveness or non-responsiveness to an anti-TNF therapy. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities (e.g., an anti-TNF therapy or a non-anti-TNF therapy) for a subject suffering from a disease such as an immune disorder.Type: ApplicationFiled: June 6, 2008Publication date: December 2, 2010Applicants: Biogen Idec MA Inc., The Feinstein Institute for Medical ResearchInventors: John P. Carulli, Peter K. Gregersen, Franak Batliwalla, Jadwiga Bienkowska, Chunyu Liu
-
Patent number: 7571055Abstract: This document relates to methods and materials involved in diagnosing SLE. For example, this document relates to methods and materials involved in diagnosing SLE, diagnosing severe SLE, and assessing a mammal's susceptibility to develop severe SLE. For example, this document provides nucleic acid arrays that can be used to diagnose SLE in a mammal. Such arrays can allow clinicians to diagnose SLE based on a simultaneous determination of the expression levels of many genes that are differentially expressed in SLE patients as compared to healthy controls. In addition, methods and materials for assessing SLE activity, determining the likelihood of experiencing active SLE, and detecting SLE treatment effectiveness are provided herein.Type: GrantFiled: October 13, 2005Date of Patent: August 4, 2009Assignees: Regents of the University of Minnesota, The Feinstein Institute for Medical ResearchInventors: Timothy W. Behrens, Emily C. Gillespie, Peter K. Gregersen
-
Publication number: 20080108058Abstract: The invention relates to methods and materials involved in diagnosing SLE. More particularly, the invention relates to methods and materials involved in diagnosing SLE, diagnosing severe SLE, and assessing a mammal's susceptibility to develop severe SLE. For example, the invention provides nucleic acid arrays that can be used to diagnose SLE in a mammal. Such arrays can allow clinicians to diagnose SLE based on a simultaneous determination of the expression levels of many genes that are differentially expressed in SLE patients as compared to healthy controls.Type: ApplicationFiled: October 3, 2006Publication date: May 8, 2008Applicants: REGENTS OF THE UNIVERSITY OF MINNESOTA, Feinstein Institute for Medical ResearchInventors: Timothy W. Behrens, Emily C. Baechler, Peter K. Gregersen
-
Patent number: 7205107Abstract: Describe herein is a CATT-tetranucleotide repeat polymorphism at position ?817 of the human Mif gene that functionally affects the activity of the Macrophage Inhibitory Factor (MIF) promoter in gene reporter assays. Four genotypes are described which comprise 5, 6, 7, or 8-CATT repeat units. Of these, the 5-CATT allele has the lowest level of basal and stimulated MIF promoter activity in vitro. The presence of the low expressing, 5-CATT repeat allele correlated with low disease severity in a cohort of rheumatoid arthritis patients. Methods, compositions and apparatus for detecting this CATT-tetranucleotide repeat polymorphism at position ?817 of the human Mif gene, and for using same for assessing predisposition to severe inflammatory disease, are also disclosed.Type: GrantFiled: December 20, 2002Date of Patent: April 17, 2007Assignee: Cytokine Pharmasciences, Inc.Inventors: John A. Baugh, Richard Bucala, Smita Chitnis, Seamus C. Donnelly, Peter K. Gregersen, Joanita Monteiro
-
Patent number: 7118865Abstract: The invention relates to methods and materials involved in diagnosing SLE. More particularly, the invention relates to methods and materials involved in diagnosing SLE, diagnosing severe SLE, and assessing a mammal's susceptibility to develop severe SLE. For example, the invention provides nucleic acid arrays that can be used to diagnose SLE in a mammal. Such arrays can allow clinicians to diagnose SLE based on a simultaneous determination of the expression levels of many genes that are differentially expressed in SLE patients as compared to healthy controls.Type: GrantFiled: August 16, 2002Date of Patent: October 10, 2006Assignees: Regents of the University of Minnesota, The Feinstein Institute for Medical ResearchInventors: Timothy W. Behrens, Emily C. Baechler, Peter K. Gregersen
-
Publication number: 20040033498Abstract: The invention relates to methods and materials involved in diagnosing SLE. More particularly, the invention relates to methods and materials involved in diagnosing SLE, diagnosing severe SLE, and assessing a mammal's susceptibility to develop severe SLE. For example, the invention provides nucleic acid arrays that can be used to diagnose SLE in a mammal. Such arrays can allow clinicians to diagnose SLE based on a simultaneous determination of the expression levels of many genes that are differentially expressed in SLE patients as compared to healthy controls.Type: ApplicationFiled: August 16, 2002Publication date: February 19, 2004Inventors: Timothy W. Behrens, Emily C. Baechler, Peter K. Gregersen
-
Publication number: 20030215446Abstract: Describe herein is a novel CATT-tetranucleotide repeat polymorphism at position −817 of the human Mif gene that functionally affects the activity of the Macrophage Inhibitory Factor (MIF) promoter in gene reporter assays. Four genotypes are described which comprise 5, 6, 7, or 8-CATT repeat units. Of these, the 5-CATT allele has the lowest level of basal and stimulated MIF promoter activity in vitro. The presence of the low expressing, 5-CATT repeat allele correlated with low disease severity in a cohort of rheumatoid arthritis patients. Methods, compositions and apparatus for detecting this CATT-tetranucleotide repeat polymorphism at position −817 of the human Mif gene, and for using same for assessing predisposition to severe inflammatory disease, are also disclosed.Type: ApplicationFiled: December 20, 2002Publication date: November 20, 2003Inventors: John A. Baugh, Richard Bucala, Smita Chitnis, Seamus C. Donnelly, Peter K. Gregersen, Joanita Monteiro